Merck touts a 60% price cut, but the drug is outdated and on the way out By: MarketWatch July 20, 2018 at 15:55 PM EDT The hepatitis C drug’s sales have declined since newer, better treatments hit the market. Read More >> Related Stocks: AbbVie Gilead Sciences Merck & Co